The present invention discloses an Asarum total polysaccharide extract with antitussive activity, an extraction method thereof and an application in the preparation of a medicine for preventing and treating coughs. The present invention proves that the Asarum total polysaccharide extract has a significant effect of suppressing cough for the first time through a large number of pharmacodynamic tests, has the therapeutic effect approximate to codeine, has the effect of prolonging the cough latent period better than codeine, and also finds that the total Asarum polysaccharide extract has the effects of reducing the cough sensitivity and suppressing the airway inflammation for the first time, has excellent preventive and therapeutic effects on various types of coughs, and can be used for preparing the medicines for preventing and treating cough-related diseases.

The present invention relates to a medicine composition for treatment of bone and joint diseases that has its ingredients (% by weight) as the dried extract of medicinal herbs: 40-75; tortoiseshell extract: 0.1-20; mixed bone extract: 0.1-20; deer antler extract: 0.1-20; salix alba extract: 5-25; nattokinase: 0.1-10; and Na-benzoate: 0-0.5, wherein the herbal medicine mixture comprises the ingredients of: Huang Bai (bark), Liquorice (root/rhizome), Hardy rubber tree (bark), Ox Knee (root), Fang Feng (root), Poria cocos wolf (fruit body), Chinese foxglove (rhizome), Sang Ji Sheng (whole tree), Gentian Root (root), Rhizoma Anemarrhena (rhizome), Peach blossom (blossom), Dried tangerine peel (peel), Chinese peony (root), Dangshen (root), Ginseng (root) Du Huo (root), Dongquai (root), Cinnamon (bough), Xi Xin (root, rhizome), Szechuan lovage (rhizome) and Dwarf umbrella tree (root). The present invention also relates to a process for producing medicine composition for treatment of bone and joint diseases mentioned above.

The present invention relates to a medicine composition for treatment of bone and joint diseases that has its ingredients (% by weight) as the dried extract of medicinal herbs: 40-75; tortoiseshell extract: 0.1-20; mixed bone extract: 0.1-20; deer antler extract: 0.1-20; salix alba extract: 5-25; nattokinase: 0.1-10; and Na-benzoate: 0-0.5, wherein the herbal medicine mixture comprises the ingredients of: Huang Bai (bark), Liquorice (root/rhizome), Hardy rubber tree (bark), Ox Knee (root), Fang Feng (root), Poria cocos wolf (fruit body), Chinese foxglove (rhizome), Sang Ji Sheng (whole tree), Gentian Root (root), Rhizoma Anemarrhena (rhizome), Peach blossom (blossom), Dried tangerine peel (peel), Chinese peony (root), Dangshen (root), Ginseng (root) Du Huo (root), Dongquai (root), Cinnamon (bough), Xi Xin (root, rhizome), Szechuan lovage (rhizome) and Dwarf umbrella tree (root). The present invention also relates to a process for producing medicine composition for treatment of bone and joint diseases mentioned above.

The present invention relates to a pharmaceutical composition for prevention or treatment of an allergic disease comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient; a method for prevention or treatment of an allergic disease using the pharmaceutical composition; and a health functional food and a feed composition for improvement of an allergic disease. The composition and method of the invention can specifically inhibit the differentiation of Th2 cells and thus can be effectively used as a composition for prevention or treatment of an allergic disease.

The present invention relates to a pharmaceutical composition for prevention or treatment of an allergic disease comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient; a method for prevention or treatment of an allergic disease using the pharmaceutical composition; and a health functional food and a feed composition for improvement of an allergic disease. The composition and method of the invention can specifically inhibit the differentiation of Th2 cells and thus can be effectively used as a composition for prevention or treatment of an allergic disease.

A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.

A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.

The present invention relates to an anticancer use of aristoloxazine C, and more specifically to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by Chemical Formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating or treating cancer by using same; and a method for isolating aristoloxazine C.

The present invention relates to an anticancer use of aristoloxazine C, and more specifically to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by Chemical Formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating or treating cancer by using same; and a method for isolating aristoloxazine C.

A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.